Zoledronic Acid Once-yearly: What Role in the Prevention of Non-vertebral Osteoporotic Fractures?

Doggrell, Sheila A

doi:10.4137/cmt.s4947

Cited by 2 publications

(3 citation statements)

References 38 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…15 A study done by Doggrell et al documented 70% reduction in vertebral fracture rate observed with zoledronic acid. [16][17][18] The health outcomes and reduced incidence with zoledronic acid once yearly (HORIZON) Extension trail, used a design with a shorter treatment period (3 years of treatment followed by 3 years of placebo or active extension) and observed that zoledronic acid administered once-yearly significantly prevented non-vertebral Osteoporosis Fractures. 19 Jun Zhang et al in his meta-analysis had documented that longer term intervention, more than 12 months interventions, could gain a better prevention effect for osteoporosis (OR, 95% CI for BMD was 3.35, 2.77-3.92; for fracture was 0.67, 0.54-0.82).…”

Section: Discussionmentioning

confidence: 99%

Efficacy of zoledronic acid infusion on bone mineral density among adult population

2019

View full text Add to dashboard Cite

Background: Osteoporosis is a skeletal disease characterised by impaired bone strength due to reduced bone mineral density. As a consequence, patients with osteoporosis are at increased risk of fractures. Zoledronic acid is an anti-resorptive agent that acts by slowing down osteoclast medicated bone resorption, thereby increasing bone density. This study was carried out to evaluate the efficacy of Zoledronic acid on bone mineral density.Methods: This study was carried out as a record based cross sectional study among 30 symptomatic adult patients who visited the outpatient department of Orthopedics for a period of two years. Bone mineral density (BMD) parameters assessed using dual-energy X-ray absorptiometry (DEXA) scan were documented for initial period and after six months of intervention. Documentation of intervention with single dose of zoledronic acid 5 mg by intravenous infusion was verified and noted.Results: There was a significant difference in the mean scores for both femoral neck and lumbar spine with respect to BMD values and T-score values between baseline parameters and values measured after 6 months of Zoledronic acid infusion. The difference was statistically significant (p<0.05).Conclusions: Single dose of zoledronic acid 5 mg by intravenous infusion was found to be effective in increasing the BMD among individuals suffering from osteopenia and osteoporosis.

show abstract

Section: Discussionmentioning

confidence: 99%

Efficacy of zoledronic acid infusion on bone mineral density among adult population

2019

View full text Add to dashboard Cite

show abstract

“…Yiğitoğlu et al saw meaningful recoveries in lumbar BMD values of two sisters with thalassemia major whom they treated with 4 mg IV zoledronic acid at intervals for 6 years (one of them had several major fractures), and reported durable efficacy during the follow-up period 27 . However, despite positive results favoring zoledronic acid treatment, it should be noted that the frequency of osteonecrosis of the jaw might increase as the dose and frequency of administration increase 10,28 . The recent detection of certain markers in urine and serum of patients with bone diseases has led to better understanding of the pathophysiology.…”

Section: Discussionmentioning

confidence: 99%

“…In recent years there have been persuasive reports indicating the efficacy and tolerability of bisphosphonates in beta-thalassemic patients. Several therapies including calcium, vitamin D, calcitonin, sex steroids, and strontium ranelate provide contribution to bone growth and remodeling [9][10][11] . Furthermore, in recently one phase 2b study was showed that denosumab is a fully human monoclonal antibody against the receptor activator of nuclear factor kappa-B ligand (RANKL) that has been licensed for the treatment of different types of osteoporosis 12,13 .…”

Section: Introductionmentioning

confidence: 99%

Zoledronik asit osteoporozlu β-talasemi hastalarında kemik mineral yoğunluğunu arttırır: Bir vaka kontrol çalışması

Evran

Gürkan

Tuli

2019

Cukurova Medical Journal

View full text Add to dashboard Cite

This study addresses the efficacy of zoledronic acid treatment in osteoporotic patients with β-thalassemia. Materials and Methods: Thirty-nine thalassemic patients were enrolled in this study. Bone mineral density was measured using Dual energy x-ray absorbtiometry (DEXA), and biochemical markers of osteoporosis in serum and urine were measured at 0, 6, and 12 months of treatment. Patients with thalassemia were randomly received either zoledronic acid 4 mg IV once every six months or calcitriol 0.25 mcg / day for 12 months. A subgroup analysis was also performed according to gonadal status. Results: There were 21 males and 18 females, mean age of 23.1 ± 1.3 and bone age of 16.3±0.35 years. At the end of 12 months, bone mineral densities of the lumbar vertebra and femoral neck significantly increased in the zoledronic acid group. In patients with hypogonadism who received hormone replacement therapy, t-scores significantly increased. Serum NTX levels indicated significant increase in both treatment groups compared with the control group at the end of the treatment. A significant increase was obtained in urinary NTX level in hypogonadal patients who received zoledronic acid, and in serum NTX and IGF-1 levels in normogonadal patients who received calcitriol. Conclusion: In our study, zoledronic acid resulted in significant improvement in bone mineral density and tscores. This improvement was in correlation with IGF-1 levels. Amaç: Bu çalışmada osteoporozu olan β-talasemi hastalarında zoledronik asit tedavisinin etkinliği incelenmiştir. Gereç ve Yöntem: Çalışmaya 33 β-talasemili hasta ile kontrol grubu olarak yaş ve cinsiyetleri uyumlu 25 sağlıklı gönüllü alındı. Hastalarda 0. 6. ve 12.aylarda DEXA ve serum ve idrarda osteoporozun bazı biyokimyasal belirteçleri ölçüldü. Talasemili hastalar 12 ay süreyle her altı ayda bir 4 mg İV zoledronik asit ve 0.25 mcg/gün kalsitriol alanlar olmak üzere rastgele iki ayrı gruba ayrıldı. Gonadal fonksiyonlarına göre de iki alt gruba ayrılarak takip edildiler. Bulgular: Hastalar yaş ortalaması 23.1±1.3 ve kemik yaşı ortalaması 16.3±0.35 yıl olan 21 erkek, 18 kadından oluşmaktaydı. On iki ay sonunda zoledronik asit grubunda lumbar vertebra ve femur boynu kemik mineral yoğunluğu anlamlı artış gösterdi. Hipogonadik olup hormon replasmanı yapılan hastalarda lumbar vertebra ve femur boynu t-skoru anlamlı artış gösterdi. Serum NTX düzeyleri tedavinin sonunda her iki tedavi grubunda da kontrol grubuna göre belirgin olarak yükselme gösterdi. Hipogonadik hastalar içinde zolendronik asit alanlarda idrar NTXdüzeylerinde, normogonadik hastalar içinde kalsitriol alanlarda idrar NTX ve serum IGF-1 düzeylerinde anlamlı artış saptandı. Sonuç: Çalışmamızda zoledronik asit kemik mineral yoğunluğu ve t-skorlarında belirgin düzelmeler sağlamıştır. Bu düzelme IGF-1 düzeyi ile korelasyon göstermiştir.

show abstract

Zoledronic Acid Once-yearly: What Role in the Prevention of Non-vertebral Osteoporotic Fractures?

Cited by 2 publications

References 38 publications

Efficacy of zoledronic acid infusion on bone mineral density among adult population

Efficacy of zoledronic acid infusion on bone mineral density among adult population

Zoledronik asit osteoporozlu β-talasemi hastalarında kemik mineral yoğunluğunu arttırır: Bir vaka kontrol çalışması

Contact Info

Product

Resources

About